The efficacy of different immunotherapy strategies to NSCLC patients after resistance to EGFR-TKIs: A retrospective study

被引：0
|
作者：
Huang, Jiuyan [1 ]
Wei, Chunhua [1 ]
Wang, Huijuan [1 ,2 ]
机构：
[1] Zhengzhou Univ, Dept Med Oncol, Affiliated Canc Hosp, 127 Dongming Rd, Zhengzhou 450008, Henan, Peoples R China
[2] Henan Canc Hosp, 127 Dongming Rd, Zhengzhou 450008, Henan, Peoples R China
来源：
ASIAN JOURNAL OF SURGERY | 2024年 / 47卷 / 11期
关键词：
Advanced NSCLC; Immunotherapy; EGFR-TKIs resistance;
D O I：
10.1016/j.asjsur.2024.05.257
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
引用
收藏
页码：5078 / 5079
页数：2
相关论文
共 50 条
  • [21] Clonal dominance of EGFR and efficacy of EGFR-tyrosine kinase inhibitors (EGFR-TKIs) in NSCLC.
    Ai, Xinghao
    Chen, Rongrong
    Cui, Jiuwei
    Zhang, Jiexia
    Lin, Wen
    Xie, Congying
    Hu, Xiaohua
    Zhang, Junping
    Jiao, Xiaodong
    Rao, Chuangzhou
    Yang, Weihua
    Chang, Lianpeng
    Xia, Xuefeng
    Yi, Xin
    Lu, Shun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [22] Circulating tumour DNA: A new biomarker to monitor resistance in NSCLC patients treated with EGFR-TKIs
    Diao, Zhenli
    Han, Yanxi
    Zhang, Rui
    Li, Jinming
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2020, 1873 (02):
  • [23] EGFR-TKIs plus chemotherapy demonstrated superior efficacy than EGFR-TKIs alone as first-line setting in advanced NSCLC patients with EGFR mutation and BIM deletion polymorphism
    Liu, Sangtian
    He, Yayi
    Jiang, Tao
    Ren, Shengxiang
    Zhou, Fei
    Zhao, Chao
    Li, Xuefei
    Zhang, Jie
    Su, Chunxia
    Chen, Xiaoxia
    Cai, Weijing
    Gao, Guanghui
    Li, Wei
    Wu, Fengying
    Li, Jiayu
    Zhao, Jing
    Hu, Qiong
    Zhao, Mingchuan
    Zhou, Caicun
    Hirsch, Fred R.
    LUNG CANCER, 2018, 120 : 82 - 87
  • [24] The differential efficacy of docetaxel according to NSCLC histology and therapeutic effect of EGFR-TKIs
    Miura, S.
    Murakami, H.
    Naito, T.
    Tsuya, A.
    Nakamura, Y.
    Kaira, K.
    Takahashi, T.
    Endo, M.
    Onozawa, Y.
    Yamamoto, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [25] Efficacy and safety of anlotinib with and without EGFR-TKIs or immunotherapy in the treatment of elder patients with non-small-cell lung cancer: a retrospective study
    Wenxian Wang
    Lan Shao
    Yibing Xu
    Zhengbo Song
    Guangyuan Lou
    Yiping Zhang
    Ming Chen
    BMC Pulmonary Medicine, 22
  • [26] Efficacy and safety of anlotinib with and without EGFR-TKIs or immunotherapy in the treatment of elder patients with non-small-cell lung cancer: a retrospective study
    Wang, Wenxian
    Shao, Lan
    Xu, Yibing
    Song, Zhengbo
    Lou, Guangyuan
    Zhang, Yiping
    Chen, Ming
    BMC PULMONARY MEDICINE, 2022, 22 (01)
  • [27] Beyond disease-progression: Clinical outcomes after EGFR-TKIs in a cohort of EGFR mutated NSCLC patients
    Tudor, Roxana Aline
    D'Silva, Adrijana
    Tremblay, Alain
    MacEachern, Paul
    Morris, Don
    Brenner, Darren
    Kopciuk, Karen
    Bebb, Dafydd Gwyn
    PLOS ONE, 2017, 12 (08):
  • [28] Bisphosphonates enhance effect of EGFR-TKIs in NSCLC patients with EGFR mutation and bone metastases
    Jiang, T.
    Zhou, C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [29] Bisphosphonates Enhance Effect of EGFR-TKIs in NSCLC Patients with EGFR Mutation and Bone Metastases
    Jiang, Tao
    Zhou, Caicun
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1236 - S1236
  • [30] The Usefulness of Liquid Biopsy for ctDNA in Patients with EGFR-Mutant NSCLC During and After Treatment with EGFR-TKIs
    Yokoyama, T.
    Naka, G.
    Ishida, H.
    Kishi, K.
    Ohashi, Y.
    Kunitoh, H.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2223 - S2223
12345